Balanced news tone
News Sentiment
DBVT sentiment intelligence
DBV Technologies news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
75/100 classification confidence.
directly relevant articles
high-authority source matches
+4.2% over one week, -5.3% over four weeks, trend inactive, and materially above fair value.
DBV Technologies Q2 Earnings Call Highlights
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
DBV Technologies Q2 Earnings Call Highlights
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 23:03
- Source
- MarketBeat
DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 21:27
- Source
- markets.businessinsider.com
DBV Technologies narrows Q2 loss, funds operations into Q3 2027
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 16 Jul 2026 21:19
- Source
- scanx.trade
DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 21:15
- Source
- markets.businessinsider.com
DBV Technologies Q2 Net Loss Narrows
- Tone
- Negative 42/100
- Event
- Market update
- Published
- 16 Jul 2026 20:14
- Source
- MT Newswires
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 18:49
- Source
- Market source
DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026
DBV Technologies announced it will host a conference call and live audio webcast on July 16, 2026, at 5:00 p.m. ET to discuss
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 Jul 2026 16:10
- Source
- GlobeNewswire
DBV Technologies Stock Breaks Its €2.75 Support Ahead of Semi-Annual Results
DBV Technologies stock is experiencing a downward trend, breaking its €2.75 support and trading below its three moving averages ahead of its semi-annual results announcement. The biotech company's stock is down 3.03% during the session, and has fallen nearly 29% over three months
- Tone
- Negative 29/100
- Event
- Earnings
- Published
- 15 Jul 2026 10:40
- Source
- Idéal Investisseur
Dbv Technologies SA (DBVT) Technical Analysis: Support, Resistance, Indicators & Moving Averages
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 07:00
- Source
- TradingKey
DBV Technologies to report Q2 2026 results on July 16
DBV Technologies is scheduled to release its second quarter 2026 financial results and provide a business update on July 16, 2026. The biopharmaceutical company will host a conference call and live webcast to discuss its performance. The company specializes in developing treatmen
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 Jul 2026 22:20
- Source
- scanx.trade
DBV Technologies' July 16 webcast will cover Q2 results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 Jul 2026 20:30
- Source
- Stock Titan
DBV Technologies Sets Q2 2026 Results Call July 16 | DBVT Stock News
DBV Technologies announced it will report its second quarter 2026 financial results and provide a business update on July 16, 2026. The company will host an investor conference call and live audio webcast at 5:00 p.m. ET to review these results. Key details for investors include
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 Jul 2026 20:20
- Source
- Stock Titan
DBV Technologies S.A. (DBVT) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for DBV Technologies S.A. (DBVT) stock, showing a current price of $15.53 with a decrease of 2.45%. It also notes that earnings information is not currently available and lacks analyst ratings in the last three months. The content include
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 Jul 2026 19:40
- Source
- www.timothysykes.com
ETFs Investing in DBV Technologies SA Sponsored ADR Stocks
This article lists Exchange Traded Funds (ETFs) that hold DBV Technologies SA Sponsored ADR stocks, sorted by market value. It provides key details for each fund, such as market value, weight, issuer, management style, expense ratio, and AUM, to help investors assess opportunitie
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 06:10
- Source
- TradingView
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 03:32
- Source
- The Globe and Mail
Citizens JMP Maintains DBV Technologies(DBVT.US) With Buy Rating, Maintains Target Price $55
Citizens JMP has reiterated its Buy rating for DBV Technologies (DBVT.US), maintaining a target price of $55. This indicates a continued positive outlook on the company's stock performance from the financial institution.
- Tone
- Positive 75/100
- Event
- Analyst action
- Published
- 08 Jul 2026 02:09
- Source
- 富途牛牛
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
DBV Technologies issued its half-year report for its liquidity contract with ODDO BHF, detailing transactions and assets from January 1, 2026, to June 30, 2026. The report showed an increase in DBV Technologies shares in the liquidity account and provided a breakdown of numerous
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 07 Jul 2026 13:41
- Source
- GlobeNewswire
DBV Technologies S.A.
DBV Technologies S.A. has issued its Half-Year Report on the liquidity contract with ODDO BHF for the period of January 1, 2026, to June 30, 2026. The report details the assets held in the liquidity account and the transactions executed within this timeframe, showing significant
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 06 Jul 2026 20:14
- Source
- Via Ritzau
DBV Technologies posts half-year liquidity contract figures
DBV Technologies released its half-year report on the liquidity contract with ODDO BHF as of June 30, 2026. The report shows the liquidity account held 146,321 shares and €396,088.22, with significant trading volumes in the first half of 2026. This contract, governed by AMF Decis
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 06 Jul 2026 20:10
- Source
- Stock Titan
DBV Technologies Stock Drops Over 2% and Breaks Its Support at €2.75
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 07:00
- Source
- Idéal Investisseur
Guggenheim Maintains DBV Technologies(DBVT.US) With Buy Rating, Maintains Target Price $51
Guggenheim has reiterated its Buy rating for DBV Technologies (DBVT.US) and maintained its target price at $51. This indicates continued confidence from the firm in the company's prospects.
- Tone
- Positive 71/100
- Event
- Analyst action
- Published
- 02 Jul 2026 00:13
- Source
- 富途牛牛
DBV Technologies Plans Q3 Filing of US Regulatory Application for Viaskin Peanut Patch
DBV Technologies announced its intention to file a regulatory application with US health authorities for its Viaskin Peanut patch in the third quarter of 2026. This move follows a pre-submission meeting with the FDA, where the company confirmed the required data for resubmission.
- Tone
- Positive 70/100
- Event
- Earnings
- Published
- 30 Jun 2026 23:09
- Source
- Moomoo
Enterprise value to revenue forward of DBV Technologies SA – FWB:DBV
This page provides financial information for DBV Technologies SA (FWB:DBV) from the Frankfurt Stock Exchange, specifically focusing on its enterprise value to revenue forward. The content indicates that the market is closed and there have been no recent trades. It is presented on
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 30 Jun 2026 19:39
- Source
- TradingView
DBV Technologies delays BLA filing for VIASKIN® Peanut Patch in kids 4-7 to Q3 2026 after FDA feedback.
DBV Technologies has announced a delay in filing its Biologics License Application (BLA) for the VIASKIN® Peanut Patch for children aged 4 to 7, pushing it to the third quarter of 2026. This postponement is a result of collaborative discussions with the FDA, aiming to optimize th
- Tone
- Negative 37/100
- Event
- Earnings
- Published
- 29 Jun 2026 21:10
- Source
- Pluang
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing
DBV Technologies announced an update on its Biologics License Application (BLA) submission for the VIASKIN® Peanut Patch for children aged four through seven years, following extensive discussions with the FDA. The company received valuable feedback regarding the organization and
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 29 Jun 2026 20:10
- Source
- The Manila Times
DBV Technologies to file VIASKIN Peanut Patch BLA in Q3 2026 after FDA feedback
DBV Technologies plans to submit its Biologics License Application (BLA) for the VIASKIN Peanut Patch in Q3 2026, after incorporating feedback from the FDA. The company engaged in detailed discussions with the FDA, receiving guidance on CMC and biostatistics, with no requests for
- Tone
- Positive 68/100
- Event
- Guidance
- Published
- 29 Jun 2026 20:10
- Source
- TradingView
DBV Technologies (NASDAQ: DBVT) targets Q3 2026 for VIASKIN Peanut BLA filing
DBV Technologies announced an updated timeline for its Biologics License Application (BLA) for the VIASKIN Peanut Patch, now targeting Q3 2026 for submission. The company has engaged in detailed discussions with the FDA, which provided feedback on data organization and formatting
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 20:10
- Source
- Stock Titan
DBV Technologies Stock Rebounds Nearly 4% and crosses its MM20
DBV Technologies stock has rebounded by nearly 4% and crossed its 20-day moving average (MM20), despite the SBF 120 index experiencing a slight decline. The biotech company's stock is trading at €2.99, one of the highest gains in the SBF 120, although medium-term benchmarks like
- Tone
- Positive 67/100
- Event
- Market update
- Published
- 29 Jun 2026 09:09
- Source
- Idéal Investisseur
A40WEX Forecast — Price Target — Prediction for 2027
This page provides a price target and forecast information for DBV Technologies SA Sponsored ADR (A40WEX), based on analysis from 8 analysts. It includes sections for actuals and estimates for EPS, revenue, and a disclaimer that this information is not investment advice.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 11:11
- Source
- TradingView
DBV Technologies SA Actuals & Estimates (EURONEXT:DBV)
This article provides comprehensive financial data and analyst estimates for DBV Technologies SA (EURONEXT:DBV). It covers the company's current stock price, historical performance, future price forecasts, earnings, revenue, market capitalization, and volatility. Key financial me
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 20:40
- Source
- TradingView